Adamantane in Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 1798
Special Issue Editor
Special Issue Information
Dear Colleagues,
The design and synthesis of safe and highly specific drug delivery systems with improved properties is a priority of the growing field of nanomedicine. Nanomedicine offers a new platform for drug delivery development, from minimizing the toxicity of pharmaceuticals to improving their efficacy. Great progress has been made in the field of cancer nanomedicine, regenerative medicine, immunotherapy, gene delivery and bioimaging. The unique structural and chemical properties of adamantane are well known and recognized in organic chemistry and pharmaceutical chemistry. They provide exceptional opportunities in the design of various adamantane-based scaffolds or carrier systems for drug delivery. Adamantane can be used in two ways; as a building block to which different functional groups are covalently bonded or as part of self-assembled supramolecular systems where adamantane is accommodated on the basis of its lipophilicity and strong host–guest interaction. Due to its lipophilicity, adamantane attachment to drugs with low hydrophobicity could increase the drug uptake through the lipidic membranes. Additional important features of adamantane are its biocompatibility and non-toxicity, as well as its low cost and easy accessibility. Nanomaterials containing adamantane and other diamondoids therefore remain highly relevant to nanomedicine, especially in the design of safe and selective drug delivery systems and molecular carriers.
Prof. Dr. Ruža Frkanec
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adamantane
- targeted drug delivery
- molecular recognition
- supramolecular self assembly
- host-guest interaction
- nanomaterials
- nanomedicine
- model lipid membranes
